 Phosphoproteins
"Phosphoproteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010750
|
| MeSH Number(s) |
D12.776.744
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phosphoproteins".
Below are MeSH descriptors whose meaning is more specific than "Phosphoproteins".
This graph shows the total number of publications written about "Phosphoproteins" by people in this website by year, and whether "Phosphoproteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 1 | 2 | 3 | | 1992 | 4 | 0 | 4 | | 1993 | 1 | 4 | 5 | | 1994 | 0 | 2 | 2 | | 1995 | 1 | 0 | 1 | | 1996 | 4 | 4 | 8 | | 1997 | 3 | 3 | 6 | | 1998 | 3 | 4 | 7 | | 1999 | 3 | 3 | 6 | | 2000 | 2 | 0 | 2 | | 2001 | 5 | 5 | 10 | | 2002 | 2 | 2 | 4 | | 2003 | 6 | 5 | 11 | | 2004 | 3 | 1 | 4 | | 2005 | 1 | 2 | 3 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 2 | 2 | 4 | | 2009 | 3 | 2 | 5 | | 2010 | 1 | 3 | 4 | | 2011 | 4 | 1 | 5 | | 2012 | 1 | 2 | 3 | | 2013 | 6 | 3 | 9 | | 2014 | 3 | 2 | 5 | | 2015 | 3 | 3 | 6 | | 2016 | 3 | 1 | 4 | | 2017 | 0 | 1 | 1 | | 2018 | 4 | 0 | 4 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphoproteins" by people in Profiles.
-
Saferali A, Tang AC, Strug LJ, Quon BS, Zlosnik J, Sandford AJ, Turvey SE. Immunomodulatory function of the cystic fibrosis modifier gene BPIFA1. PLoS One. 2020; 15(1):e0227067.
-
Islam SS, Uddin M, Noman ASM, Akter H, Dity NJ, Basiruzzman M, Uddin F, Ahsan J, Annoor S, Alaiya AA, Al-Alwan M, Yeger H, Farhat WA. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1. EBioMedicine. 2019 May; 43:211-224.
-
Veggiani G, Huang H, Yates BP, Tong J, Kaneko T, Joshi R, Li SSC, Moran MF, Gish G, Sidhu SS. Engineered SH2 domains with tailored specificities and enhanced affinities for phosphoproteome analysis. Protein Sci. 2019 02; 28(2):403-413.
-
Purzner T, Purzner J, Buckstaff T, Cozza G, Gholamin S, Rusert JM, Hartl TA, Sanders J, Conley N, Ge X, Langan M, Ramaswamy V, Ellis L, Litzenburger U, Bolin S, Theruvath J, Nitta R, Qi L, Li XN, Li G, Taylor MD, Wechsler-Reya RJ, Pinna LA, Cho YJ, Fuller MT, Elias JE, Scott MP. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Sci Signal. 2018 09 11; 11(547).
-
Gill MK, Christova T, Zhang YY, Gregorieff A, Zhang L, Narimatsu M, Song S, Xiong S, Couzens AL, Tong J, Krieger JR, Moran MF, Zlotta AR, van der Kwast TH, Gingras AC, Sicheri F, Wrana JL, Attisano L. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. Nat Commun. 2018 08 29; 9(1):3510.
-
van de Geer A, Nieto-Patlán A, Kuhns DB, Tool AT, Arias AA, Bouaziz M, de Boer M, Franco JL, Gazendam RP, van Hamme JL, van Houdt M, van Leeuwen K, Verkuijlen PJ, van den Berg TK, Alzate JF, Arango-Franco CA, Batura V, Bernasconi AR, Boardman B, Booth C, Burns SO, Cabarcas F, Bensussan NC, Charbit-Henrion F, Corveleyn A, Deswarte C, Azcoiti ME, Foell D, Gallin JI, Garcés C, Guedes M, Hinze CH, Holland SM, Hughes SM, Ibañez P, Malech HL, Meyts I, Moncada-Velez M, Moriya K, Neves E, Oleastro M, Perez L, Rattina V, Oleaga-Quintas C, Warner N, Muise AM, López JS, Trindade E, Vasconcelos J, Vermeire S, Wittkowski H, Worth A, Abel L, Dinauer MC, Arkwright PD, Roos D, Casanova JL, Kuijpers TW, Bustamante J. Inherited p40phox deficiency differs from classic chronic granulomatous disease. J Clin Invest. 2018 08 31; 128(9):3957-3975.
-
Hirai M, Arita Y, McGlade CJ, Lee KF, Chen J, Evans SM. Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest. 2017 Feb 01; 127(2):569-582.
-
Oudhoff MJ, Braam MJS, Freeman SA, Wong D, Rattray DG, Wang J, Antignano F, Snyder K, Refaeli I, Hughes MR, McNagny KM, Gold MR, Arrowsmith CH, Sato T, Rossi FMV, Tatlock JH, Owen DR, Brown PJ, Zaph C. SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/ß-Catenin and Hippo/YAP Signaling. Dev Cell. 2016 Apr 04; 37(1):47-57.
-
Posfai E, Rossant J. Depending on maternal Yap. Cell Res. 2016 Apr; 26(4):393-4.
-
Abbassi L, Malki S, Cockburn K, Macaulay A, Robert C, Rossant J, Clarke HJ. Multiple Mechanisms Cooperate to Constitutively Exclude the Transcriptional Co-Activator YAP from the Nucleus During Murine Oogenesis. Biol Reprod. 2016 05; 94(5):102.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|